My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every time.
Start Research-backed Investing ...in less than a minute.
BSE: 524816 | NSE: NATCOPHARM | Pharmaceuticals & Drugs | Mid Cap
1. Is Natco Pharma Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Natco Pharma Ltd is a good quality company.
2. Is Natco Pharma Ltd undervalued or overvalued?
The key valuation ratios of Natco Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Natco Pharma Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Natco Pharma Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | 12.4% | 13.7% | 16.5% | 14.7% | 31.1% | 26.8% | 18% | 11.4% | 6.8% | 2.5% | - | ||
| Value Creation Index ⓘ | -0.1 | -0.0 | 0.2 | 0.1 | 1.3 | 1.0 | 0.3 | -0.2 | -0.5 | -0.8 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 558 | 622 | 716 | 1,021 | 1,958 | 2,091 | 1,986 | 1,790 | 1,654 | 1,768 | 2,084 | ||
| YoY Gr. Rt. % | - | 11.6% | 15% | 42.7% | 91.7% | 6.8% | -5% | -9.9% | -7.6% | 6.9% | - | ||
| Adj EPS ⓘ | 5.2 | 6.2 | 9.5 | 10.2 | 29.3 | 37.3 | 35 | 24.6 | 15.5 | 5.6 | 17.6 | ||
| YoY Gr. Rt. % | - | 18.2% | 53.7% | 8% | 186.7% | 27.3% | -6.2% | -29.7% | -37.3% | -64.1% | - | ||
| BVPS (₹) ⓘ | 34.3 | 44.3 | 52.9 | 76.2 | 96.5 | 168.1 | 193.6 | 211.3 | 223.2 | 229.5 | 246.5 | ||
| Adj Net Profit ⓘ | 81.8 | 102 | 157 | 178 | 511 | 689 | 640 | 449 | 282 | 101 | 322 | ||
| Cash Flow from Ops. ⓘ | 70 | 172 | 125 | 190 | 330 | 476 | 699 | 423 | 184 | 57.7 | - | ||
| Debt/CF from Ops. ⓘ | 4.8 | 1.4 | 2.5 | 0.6 | 0.7 | 0.4 | 0.6 | 0.7 | 1.4 | 6.7 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 13.7% | -2% | -3.8% | 6.9% | ||||||||
| Adj EPS ⓘ | 0.7% | -28.3% | -45.9% | -64.1% | ||||||||
| BVPS ⓘ | 23.5 | 18.9 | 5.8 | 2.8 | ||||||||
| Share Price | 20.5% | -6.9% | 0.8% | -32.4% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | 16.3 | 16.1 | 19.5 | 16.1 | 33.7 | 28.6 | 19.1 | 12.1 | 7.1 | 2.4 | 7.4 | |
| Op. Profit Mgn % ⓘ | 28.1 | 30 | 31.9 | 28 | 36.8 | 44.4 | 41.1 | 32.3 | 25.1 | 12.1 | 23 | |
| Net Profit Mgn % ⓘ | 14.7 | 16.4 | 22 | 17.5 | 26.1 | 32.9 | 32.2 | 25.1 | 17.1 | 5.7 | 15.4 | |
| Debt to Equity ⓘ | 0.6 | 0.3 | 0.4 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | - | |
| Working Cap Days ⓘ | 238 | 256 | 261 | 237 | 169 | 258 | 328 | 416 | 458 | 391 | 0 | |
| Cash Conv. Cycle ⓘ | 60 | 69 | 85 | 76 | 49 | 77 | 97 | 133 | 187 | 209 | 0 | |
Return on Equity has increased versus last 3 years average to 7.40%
Sales growth is good in last 4 quarters at 38.48%
Sales growth has been subdued in last 3 years -3.81%
Net Profit has been subdued in last 3 years -45.89%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 17.6 | 21.3 |
| TTM Sales (₹ Cr.) | 2,084 | 2,406 |
| BVPS (₹.) ⓘ | 246.5 | 253.8 |
| Reserves (₹ Cr.) ⓘ | 4,463 | 4,597 |
| P/BV ⓘ | 2.19 | 2.11 |
| PE ⓘ | 30.59 | 25.17 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 502.00 / 846.70 |
| All Time Low / High (₹) | 1.60 / 1188.95 |
| Market Cap (₹ Cr.) | 9,840 |
| Equity (₹ Cr.) | 36.5 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 35.4 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Natco Pharma was promoted by V C Nannapaneni in the year 1981 as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh. The company focus is primarily on niche therapeutic areas and complex products. It market and distribute products in various countries. It also operates in certain key geographies through its subsidiaries.
Natco Pharma manufactures API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets. In the API segment, company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.
Business area of the company
Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). It is also engaged in contract manufacturing business, whereby it undertake selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. It has diversified into the business of crop health sciences to leverage is skills in organic chemistry.
Products:
Milestone:
Download APP
